Author： Nohynek G.J. Schaefer H.
Publisher： Academic Press
ISSN： 0273-2300
Source： Regulatory Toxicology and Pharmacology, Vol.33, Iss.3, 2001-06, pp. : 285-299
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
PharmacoEconomics, Vol. 28, Iss. 11, 2010-11 ,pp. :
Access to resources
Recommend
Cardiovascular Risk-Benefit Profile of Sibutramine
By Scheen A.J.
American Journal of Cardiovascular Drugs, Vol. 10, Iss. 5, 2010-10 ,pp. :
A Risk-Benefit Assessment of Abciximab in Angioplasty
By Kleiman N.S.
Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. :
A Risk-Benefit Assessment of Amifostine in Cytoprotection
By Mabro M.
Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. :
Risk–benefit effects of tocolytic therapy
By Pryde Peter G Janeczek Susan Mittendorf Robert
Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. :